Oncology’s Next Decade: The Therapies and Players Reshaping a $400bn Future
Drawing on Evaluate Pharma consensus forecasts and analysis from the In Vivo editorial team, this report looks at the oncology competitive landscape and where the market is heading through 2032.
The report covers:
- The shifting therapy mix, from chemotherapy’s declining share to the rise of targeted agents, immunotherapies, and cell and gene therapies, which could reach ~7% of oncology spend by 2032
- The cancer types commanding the largest and fastest-growing drug markets, and what that means for oncology portfolio strategy
- How regional dynamics are evolving, including China’s rapid emergence as both a development and commercial market
- The oncology competitive landscape among the top companies, and how patent expirations are set to redraw the rankings by 2032
- Where the next wave of oncology revenues may come from; bispecific antibodies, mRNA cancer vaccines, and next-generation CAR-T therapies
